Evidence map›Paper›PMID 35277970›Full record

ArticleInternational journal of cancer2022

Global patterns in testicular cancer incidence and mortality in 2020.

Ariana Znaor, Niels Erik Skakkebaek, Ewa Rajpert-De Meyts, Tomislav Kuliš, Mathieu Laversanne, Jason Gurney, Diana Sarfati, Katherine A McGlynn, Freddie Bray

Abstract read
In one paragraph

Article in International journal of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Guideline
  2. Survivorship Post-Retroperitoneal Lymph Node Dissection for Metastatic Testicular Cancer: A Systematic Review.International journal of urology : official journal of the Japanese Urological Association · 2025
    Pooled it
  3. Pooled it
  4. Trial
  5. Is radiotherapy still an option for residual retroperitoneal masses in stage IIC seminoma?Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  6. Article
  7. Article
  8. Incidence, mortality and survival of testicular germ cell cancer in the province of Tarragona (Spain), 1980-2018.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Oxidative Stress and Male Reproductive Health-First Edition.Antioxidants (Basel, Switzerland) · 2026
    Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ariana ZnaorSection of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France.ORCID 0000-0002-5849-4782
Niels Erik SkakkebaekDepartment of Growth & Reproduction, Copenhagen University Hospital (Ringshospitalet), Copenhagen, Denmark.
Ewa Rajpert-De MeytsDepartment of Growth & Reproduction, Copenhagen University Hospital (Ringshospitalet), Copenhagen, Denmark.
Tomislav KulišDepartment of Urology, University Hospital Centre Zagreb, Zagreb, Croatia.
Mathieu LaversanneSection of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France.
Jason GurneyDepartment of Urology, University Hospital Centre Zagreb, Zagreb, Croatia.
Diana SarfatiDepartment of Public Health, University of Otago, Wellington, New Zealand.ORCID 0000-0002-2425-4086
Katherine A McGlynnDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.ORCID 0000-0003-2329-9933
Freddie BraySection of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France.ORCID 0000-0002-3248-7787

Funding

Hormone-Related CancersZIACP010126 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI GIERACH, GRETCHEN · 2009 to 2025
$103.5M
NCCDPHP CDC HHS U58 DP004954World Health Organization 001
6 · The paper itself

Abstract

With 74 500 new cases worldwide in 2020, testicular cancer ranks as the 20th leading cancer type, but is the most common cancer in young men of European ancestry. While testicular cancer incidence has been rising in many populations, mortality trends, at least those in high-income settings, have been in decline since the 1970s following the introduction of platinum-based chemotherapy. To examine current incidence and mortality patterns, we extracted the new cases of, and deaths from cancers of the testis from the GLOBOCAN 2020 database. In 2020, testicular cancer was the most common cancer in men aged 15 to 44 in 62 countries worldwide. Incidence rates were highest in West-, North- and South-Europe and Oceania (age-standardised rate, ASR ≥7/100 000), followed by North America (5.6/100 000 and lowest (<2/100 000) in Asia and Africa. The mortality rates were highest in Central and South America (0.84 and 0.54 per 100 000, respectively), followed by Eastern and Southern Europe, and Western and Southern Africa. The lowest mortality rates were in Northern Europe, Northern Africa and Eastern Asia (0.16, 0.14, 0.9 per 100 000, respectively). At the country level, incidence rates varied over 100-fold, from 10/100 000 in Norway, Slovenia, Denmark and Germany to ≤0.10/100 000 in Gambia, Guinea, Liberia, Lesotho. Mortality rates were highest in Fiji, Argentina and Mexico. Our results indicate a higher mortality burden in countries undergoing economic transitions and reinforce the need for more equitable access to testicular cancer diagnosis and treatment globally.

Indexed as

Neoplasms, Germ Cell and EmbryonalTesticular NeoplasmsEuropeGlobal HealthHumansIncidenceMaleincidencemortalitytesticular cancer

Identifiers

PMID35277970
PMCPMC12980092

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.